Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT03273426 Completed - Breast Neoplasm Clinical Trials

Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.

Start date: September 8, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the ability of preoperative biopsy to predict correctly pathologic complete response in breast cancer patients with complete clinical response after neoadjuvant chemotherapy.

NCT ID: NCT03273348 Not yet recruiting - Breast Cancer Clinical Trials

Role of Oncoplastic Breast Surgery In Breast Cancer Treatement

Start date: September 28, 2017
Phase: N/A
Study type: Interventional

Role of Oncoplastic Breast Surgery In Breast Cancer Treatement

NCT ID: NCT03272477 Completed - Breast Neoplasms Clinical Trials

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

TP-II
Start date: October 5, 2017
Phase: Phase 2
Study type: Interventional

This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks with a quality of life assessment for 40 additional weeks in patients with operable HER2+/HR+ breast cancer.

NCT ID: NCT03272334 Recruiting - Clinical trials for Metastatic Breast Cancer

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

Breast-47
Start date: December 29, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC). Phase I will determine a safe dose of the combination of PBZ and HER2 BATs in 3 to 18 patients. In the phase II portion, an additional 12 patients will be treated at the selected dose to further evaluate the safety and preliminary efficacy. Study treatment includes a combination of 8 infusions of BATs using a previously established schedule and one to three infusions of PBZ (200 mg per dose). PBZ will be added to 8 infusions of BATs in 3 schedules: #1) after the 8th BATs infusion; #2) after the 4th and 8th BATs infusions; and then, #3) before the 1st and after the 4th and 8th BATs infusions.

NCT ID: NCT03271853 Suspended - Clinical trials for Breast Neoplasm Female

Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.

Start date: November 3, 2017
Phase: N/A
Study type: Observational

This study is designed to evaluate the Sentinel BreastScan II as well as the analysis of data by Therma-Scan.

NCT ID: NCT03271476 Completed - Breast Cancer Clinical Trials

EMDR Psychotherapy to Treat Anxious-depressive Symptoms in Breast Cancer Patient

PSYCANCER
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

The study will consist in an adjustment/adaptation of the "standard EMDR protocol" for cancer disease, and most particulary for women who present a breast cancer and during adjuvant therapy. It will also test the faisability of the research, with a view to adjust the calendar and the ressources to put at disposal for a randomized control trial that follow. This study will also allow to test the need and acceptibility of this new psychotherapy for the patient, and to identify facilitators and obstacles : participation/rejection ratio, inclusion rythm, adhesion of the medical staff about the project

NCT ID: NCT03270995 Completed - Breast Neoplasms Clinical Trials

Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study

Start date: October 2014
Phase: N/A
Study type: Interventional

Studies show that cancer survivors have unmet needs, the most frequently cited being fear of recurrence (FCR). Moderate to high levels of FCR have been reported by as much as 49% of cancer patients and are more prevalent among women. FCR is associated with psychological distress, lower quality of life, and increased health care utilization. Little evidence exists that these problems are being addressed by current medical management.

NCT ID: NCT03270111 Completed - Clinical trials for Breast Cancer Female

High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women

Start date: September 25, 2017
Phase: N/A
Study type: Interventional

The purpose of this second pilot study is to extend the feasibility demonstrated in NCT02963740 that the intervention achieves high levels of moderate to vigorous physical activity (MVI PA) and modulates risk biomarkers for breast cancer and cardiovascular disease in older, obese sedentary breast cancer survivors who are undergoing moderate calorie restriction.

NCT ID: NCT03270072 Recruiting - Clinical trials for Breast Cancer Stage II

The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients

Start date: October 26, 2017
Phase:
Study type: Observational

The objective of the study is to serve as a correlative study for patients enrolled on the RadCOMP trial (NCT02603341), a randomized phase III study of stage II and III breast cancer patients treated with either conventional photon radiation or proton beam radiation

NCT ID: NCT03270007 Recruiting - Clinical trials for Primary Breast Cancer

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Start date: November 10, 2017
Phase: Phase 4
Study type: Interventional

This is a phase IV, single-center, prospective, open-label, randomized,controlled study